Immuno-Oncology
We aim to set new standards of cancer care with our immuno-oncology treatments.
The foundation of our immuno-oncology franchise is built upon LOQTORZI™ (toripalimab-tpzi), a next-generation PD-1 inhibitor, which is the first and only FDA-approved treatment indicated in combination with chemotherapy for recurrent or metastatic nasopharyngeal carcinoma (NPC), and has demonstrated improvement in the overall survival of cancer patients in several tumor types. LOQTORZI is in development for the treatment of additional tumor types with the goal of being the PD-1/ICI backbone of future treatment combinations that may extend survival for patients.
We believe improvement in overall survival must come from novel combinations that more broadly target the immune system and particularly mechanisms of PD-1 resistance.
Coherus’ earlier-stage immuno-oncology pipeline targets immune-suppressive mechanisms, including CHS-1000, a preclinical program targeting the novel pathway ILT4 which is expected to enter clinical trials in Q1 2024. With our immuno-oncology pipeline, we are focusing development efforts on delivering breakthrough survival benefits for cancer patients, beyond the efficacy with existing chemotherapy plus checkpoint inhibitor regimens.